Plain-English translation of NCT05703971 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called combined with (an immunotherapy drug) for people with advanced small cell lung cancer. You would receive this medication only after you've completed initial chemotherapy and immunotherapy and your cancer has not gotten worse. The goal is to see if this combination can help keep your cancer under control for longer.
Small cell lung cancer is an aggressive type of cancer, and while initial chemotherapy and immunotherapy help some patients, doctors need better options to prevent the cancer from coming back or growing. This medication is designed to work in a new way by using gene therapy to boost your body's immune system, and researchers want to see if combining it with immunotherapy can improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an IV infusion once every 3 weeks for as long as your cancer does not get worse and you can tolerate the side effects. In Phase 2 of the study (where new patients are being enrolled), you may receive the gene therapy medication combined with the immunotherapy drug, or the immunotherapy combined with a different form of administration. You will have regular visits with your doctor for blood tests, imaging scans, and check-ups to monitor how you're responding and watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States